NCT03382964View on ClinicalTrials.gov

Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

July 13, 2018

Study Completion Date

July 28, 2019

Conditions

Chikungunya

Interventions

BIOLOGICAL

VLA1553

I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate

Trial Locations (2)

35802

Optimal Research, LLC, Huntsville

61614

Optimal Research, LLC, Peoria

All Listed Sponsors

lead

Valneva Austria GmbH

INDUSTRY

NCT03382964 - Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers | Biotech Hunter | Biotech Hunter